Valneva shares jump 30% after saying vaccine candidate outperformed AstraZeneca's

Valneva shares jump 30% after saying vaccine candidate outperformed AstraZeneca's

Valneva shares jumped 30% in Paris trading after saying its coronavirus vaccine candidate outperformed AstraZeneca's in a Phase 3 study, which met both its co-primary endpoints. Valneva said its vaccine had a neutralizing antibody seroconversion rate above 95% and that it had a better tolerability profile.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting